This page shows the latest SGLT2 inhibitor news and features for those working in and with pharma, biotech and healthcare.
AZ data suggest SGLT2 inhibitors can reduce heart failure risk. Publishes real-world data for study involving Forxiga/Farxiga, Invokana and Jardiance. ... Real-world evidence has shown that treatment with the newer SGLT2 inhibitor class of diabetes drug
Merck (known as MSD outside North America) and Pfizer have been working together on ertugliflozin's development since 2013, but are late to the SGLT2 inhibitor party as there are already ... The first SGLT2 inhibitor to be approved in the US was Johnson
Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin). ... The FDA turned down Qtern with a request for more data 16 months ago,
waited for data from a cardiovascular outcomes trial involving rival SGLT2 inhibitor Invokana (canagliflozin) from Johnson &Johnson, due to report next year. ... Another SGLT1 inhibitor - Bristol-Myers Squibb/AstraZeneca's Forxiga/Farxiga (dapagliflozin)
Currently in the final stages of consultation, the guidance endorses the use of AstraZeneca's SGLT2 inhibitor Forxiga (dapagliflozin) in patients already taking two drugs for blood sugar control without success. ... It has since been backed as a
SGLT2 inhibitor Forxiga (dapagliflozin) is one of AZ's fastest-growing products, with sales rising nearly 90% to $376m in the first half of the year. ... It is however facing intense competition from Boehringer Ingelheim and Eli Lilly's rival SGLT2
More from news
Approximately 1 fully matching, plus 53 partially matching documents found.
Company acquisition. Marketed BTK inhibitor for haematological cancers pipeline incl. 3 products in clinic. ... 165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.
Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The deal gives
The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a ... Clearly the pressure is on, the announcement coming only a
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Pfizer's interests in the area include a collaboration with Merck &Co on the sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin to treat diabetes.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...